Search alternatives:
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), use decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
0 decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
09 0 » 0 0 (Expand Search), 01 0 (Expand Search), 05 0 (Expand Search)
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), use decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
0 decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
09 0 » 0 0 (Expand Search), 01 0 (Expand Search), 05 0 (Expand Search)
-
441
-
442
-
443
Differences among the classes of CAMs.
Published 2025“…Some <i>N</i>-hydroxypyridinedione (HPD) HBV RNaseH inhibitors significantly reduced accumulation of capsids in HBV-replicating cells. A representative HPD <b>1466</b>, with a 50% effective concentration against HBV replication of 0.25 µM, decreased capsid and core protein accumulation by 50–90% in HepDES19 and HepG2.2.15 cells. …”
-
444
-
445
-
446
-
447
-
448
-
449
-
450
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
-
451
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
-
452
-
453
Discovery of Dual-Acting Biofilm Inhibitors against Pseudomonas aeruginosa by the Coupling of 3‑Hydroxypyridin-4(1<i>H</i>)‑ones with <i>N</i>‑Phenylamide QS Inhibitors
Published 2025“…Mechanistic studies revealed that there was a decreased production of virulence regulated by quorum sensing system and a lack of iron acquisition under the treatment of <b>19l</b>, which led to the inhibition of biofilm. …”
-
454
-
455
-
456
-
457
Sensitivity analysis of 50:50 model.
Published 2021“…<p>A sensitivity analysis was conducted on the 50:50 model with constant 120 pA current to determine the sensitivity of pain output to select model parameters before injury (t = 10), during injury (t = 105), and after injury (t = 240). …”
-
458
-
459
Loss of cytoplasmic incompatibility in <i>Wolbachia</i>-infected <i>Aedes aegypti</i> under field conditions
Published 2019“…To investigate the critical temperature range for the loss of <i>Wolbachia</i> infections, we held <i>Ae</i>. <i>aegypti</i> eggs in thermocyclers for one week at a range of cyclical temperatures. …”
-
460